CriticalFirst-generation antipsychotic, butyrophenone. Used as antiemetic.×First-generation antipsychotic, diphenylbutylpiperidine derivative
Updated · Methodology
Mechanism
Pimozide prolongs the QT interval, and ventricular arrhythmias, torsade de pointes and sudden death have been reported with it, including at usual doses (pimozide summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, and pimozide label, US Food and Drug Administration, FDA). Droperidol also prolongs the QT interval in a dose-dependent way. In 40 surgical patients without known heart disease, the median heart-rate-corrected QT rose by 37, 44 and 59 ms within 10 minutes of doses of 0.1, 0.175 and 0.25 mg/kg (FDA droperidol label). The US pimozide label anticipates an additive effect on QT with other QT-prolonging drugs (FDA pimozide label). Both drugs block dopamine receptors in the brain, and according to the Spanish droperidol SmPC, extrapyramidal disorders become more frequent with other neuroleptics (pimozide and droperidol SmPCs, AEMPS). CYP3A4, CYP2D6 and CYP1A2 metabolise pimozide, and CYP1A2 and CYP3A4 metabolise droperidol (pimozide and droperidol SmPCs, AEMPS). The documents do not describe either drug as an inhibitor of these enzymes and give no data on how one drug changes the level of the other.
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). A ventricular arrhythmia causes palpitations, dizziness or fainting and can lead to cardiac arrest. With droperidol, QT prolongation, torsade de pointes, ventricular arrhythmias, cardiac arrest and sudden death have been reported, including at or below recommended doses and in people with no known risk factors (droperidol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, and droperidol label, US Food and Drug Administration, FDA). With pimozide, QT prolongation, ventricular arrhythmias and torsade de pointes have been reported very rarely, as well as ventricular tachycardia and ventricular fibrillation, sometimes fatal, cardiac arrest and sudden death (pimozide SmPC, AEMPS). When combined with other neuroleptics, droperidol more often causes extrapyramidal disorders such as dystonia, oculogyric crisis and tremor (droperidol SmPC, AEMPS). The risk of arrhythmia is higher with low potassium or magnesium and a slow heart rate (pimozide and droperidol SmPCs, AEMPS).
Management
The combination is contraindicated. The Spanish pimozide summary of product characteristics (SmPC) contraindicates pimozide with drugs known to prolong the QT interval, including other antipsychotics. The Spanish droperidol SmPC contraindicates droperidol in patients treated with QT-prolonging drugs and lists certain antipsychotics among the drugs that must not be given with it (pimozide and droperidol SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). The documents of each drug describe QT prolongation, so both contraindications apply to this pair (pimozide and droperidol SmPCs, AEMPS, and labels, US Food and Drug Administration, FDA). The US pimozide label also contraindicates pimozide with QT-prolonging drugs and names droperidol. The US droperidol label states that any drug that can prolong the QT interval should not be used with droperidol (pimozide and droperidol labels, FDA). In Spain, droperidol is available only for intravenous use against postoperative nausea and vomiting, including nausea and vomiting caused by morphine and its derivatives during postoperative pain relief (droperidol SmPC, AEMPS). No document states how long to wait after stopping pimozide before giving droperidol. The mean half-life of pimozide is about 55 hours, with wide variation between people (pimozide SmPC, AEMPS). Droperidol is also contraindicated in known or suspected QT prolongation, that is, a heart-rate-corrected QT (QTc) above 450 ms in women and above 440 ms in men. Low potassium or magnesium and a heart rate below 55 beats per minute are contraindications too (droperidol SmPC, AEMPS). The US label calls for a 12-lead electrocardiogram (ECG) in all patients before droperidol (FDA droperidol label). Pimozide is contraindicated in low potassium or magnesium and clinically significant bradycardia. Do an ECG before starting pimozide and repeat it periodically, and stop pimozide if the QT or QTc exceeds 500 ms (pimozide SmPC, AEMPS). Also avoid combining droperidol with other neuroleptics, because extrapyramidal disorders become more frequent (droperidol SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Pimozide tablets, USP (ANI Pharmaceuticals) – prescribing information (2026)– FDA label, ANI Pharmaceuticals, DailyMed setid 4e954fc2-fdff-486c-beb6-2b8ace717081, version 3, 07/2026, INDICATIONS AND USAGE, CONTRAINDICATIONS, PRECAUTIONS: Drug Interactions
- FDA: Inapsine (droperidol) prescribing information (2007)– FDA Inapsine label, boxed warning QT
- AEMPS: Ficha técnica: Orap (pimozida) (nº registro 49503), secciones 4.3 y 4.5 (2026)– AEMPS, CIMA, nº registro 49503, revisión 10/2026, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Droperidol (nº registro 69837), sección 4.5 (2023)– AEMPS, CIMA, nº registro 69837 (Xomolix 2,5 mg/ml solución inyectable, Substipharm), revisión 08/2023, secciones 4.2, 4.3, 4.4, 4.5 y 4.8